Biotech companies could have their say in setting up standards for regulatory approval of cutting edge drugs, as they benefit from parallel scientific advice from Europe and the US.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
EMEA approves OGS drug rejected by FDA
FDA plans to improve and accelerate product reviews
Related external links
Rights and permissions
About this article
Cite this article
Katsnelson, A. FDA and EMEA pool scientific advice. Nat Biotechnol 22, 1490–1491 (2004). https://doi.org/10.1038/nbt1204-1490
Issue Date:
DOI: https://doi.org/10.1038/nbt1204-1490
This article is cited by
-
Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude
Clinical Pharmacology & Therapeutics (2013)
-
Typical pitfalls in applications for marketing authorization of biotechnological products in Europe
Nature Reviews Drug Discovery (2008)
-
Overhauling oversight—European drug legislation
Nature Biotechnology (2005)
-
Europe's new policies bail out ailing pharma companies
Nature Medicine (2005)
-
Cautious welcome for FDA pharmacogenomics guidance
Nature Biotechnology (2005)